Amylyx Pharmaceuticals, Inc. (AMLX)
AMLX moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How AMLX actually reacts to news — the realized, point-in-time move the market made, measured across 1,147 labeled events over the last three years with zero look-ahead.
AMLX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 1,147 |
| 30-min | 0.00% | 47% | 1,147 |
| 60-min | -0.08% | 47% | 1,147 |
| to close | 0.00% | 46% | 1,143 |
| Middle 50% of AMLX reactions | -1.03% to +1.29% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 1,147 |
Half of all Amylyx Pharmaceuticals, Inc. news events land between -1.03% and +1.29% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AMLX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 17 | -1.85% | 41% | 0.00% |
| Analyst downgrades | 16 | +1.74% | 63% | +1.36% |
| Coverage initiations | 22 | -0.85% | 32% | +1.78% |
| Rating reiterations | 54 | +0.30% | 56% | -0.08% |
| Price-target raises | 23 | +0.17% | 52% | -0.32% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how AMLX ranks against every other measured name →
That’s how AMLX usually reacts — get an email when it moves on news →Email me when AMLX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AMLX's baseline. Nothing else.
Recent AMLX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting | Press release | Business Wire | +0.43% | +0.25% | |
| Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum | Press release | Business Wire | +0.30% | -6.92% | |
| Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors | Press release | Business Wire | +1.21% | -3.28% | |
| Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference | Press release | Business Wire | -0.21% | +1.17% | |
| Form 8-K Amylyx Pharmaceuticals, For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | +1.21% | -3.28% | |
| Form 8-K Amylyx Pharmaceuticals, For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | -3.18% | |
| Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock | Press release | Business Wire | +3.71% | +5.06% | |
| Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock | Press release | Business Wire | -0.04% | +6.84% | |
| Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia | Press release | Business Wire | +1.25% | +17.03% | |
| Form 8-K Amylyx Pharmaceuticals, For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | +1.25% | +17.03% | |
| Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 | Press release | Business Wire | +1.25% | +17.03% | |
| Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results | Press release | Business Wire | +10.13% | +12.98% | |
| Form 10-Q Amylyx Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +10.13% | +12.98% | |
| Form 8-K Amylyx Pharmaceuticals, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +10.13% | +12.98% | |
| Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | Business Wire | -1.09% | -0.15% | |
| Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? | Press release | PR Newswire | +0.83% | -0.22% | |
| Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 | Press release | Business Wire | +2.16% | +2.31% | |
| Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026 | Press release | Business Wire | -0.44% | -4.06% | |
| Form 8-K Amylyx Pharmaceuticals, For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +0.56% | -6.53% | |
| Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation | Press release | Business Wire | +0.04% | -0.30% | |
| Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results | Press release | Business Wire | -1.21% | -4.88% | |
| Form 10-Q Amylyx Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.21% | -4.88% | |
| Form 8-K Amylyx Pharmaceuticals, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -1.21% | -4.88% | |
| Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | Business Wire | -1.82% | -2.73% | |
| Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia | Press release | Business Wire | +0.75% | -1.08% | |
| Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | Business Wire | +0.77% | +2.37% | |
| Form ARS Amylyx Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.83% | -1.14% | |
| Form DEF 14A Amylyx Pharmaceuticals, For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +0.83% | -1.14% | |
| Form DEFA14A Amylyx Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | +0.83% | -1.14% | |
| Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? | Press release | PR Newswire | -0.63% | -5.76% | |
| Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference | Press release | Business Wire | -1.84% | +0.95% | |
| Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia | Press release | Business Wire | +1.05% | +2.09% | |
| Form 8-K Amylyx Pharmaceuticals, For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +1.05% | +2.09% | |
| Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | -4.05% | -8.49% | |
| Form 10-K Amylyx Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.05% | -8.49% | |
| Form 8-K Amylyx Pharmaceuticals, For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -4.05% | -8.49% | |
| Form S-3ASR Amylyx Pharmaceuticals, | SEC filing · Form S-3ASR | SEC EDGAR | -4.05% | -8.49% | |
| Form S-8 Amylyx Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | -0.92% | +6.96% | |
| Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences | Press release | Business Wire | +0.73% | +6.56% | |
| Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 | Press release | Business Wire | +2.01% | +5.83% | |
| HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS | Press release | PR Newswire | +1.56% | -3.18% | |
| Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S | Press release | Business Wire | -1.18% | -0.51% | |
| Form 8-K Amylyx Pharmaceuticals, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -1.18% | -0.51% | |
| Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial | Press release | Business Wire | +1.24% | -2.34% | |
| HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS | Press release | PR Newswire | -0.61% | -2.93% | |
| Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results | Press release | Business Wire | -3.66% | -4.01% | |
| Form 10-Q Amylyx Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.66% | -4.01% | |
| Form 8-K Amylyx Pharmaceuticals, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -3.66% | -4.01% | |
| Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf | Press release | GlobeNewswire | +0.42% | -1.11% | |
| Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences | Press release | Business Wire | +0.34% | +1.46% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AMLX section they belong to.
Where else AMLX is measured.
AMLX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Amylyx Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled AMLX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,147 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of AMLX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AMLX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.